Family Medicine Doctors in Marietta, PA Accepting Medicare
5 Family Medicine doctors found. Showing 1 - 5
 Jill M Herr, M.D. Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 1159 River Rd, Marietta, PA 17547 Phone: 717-426-1131 Fax: 717-426-2068 |
 Robert H Brewer, M.D. Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 1159 River Rd, Marietta, PA 17547 Phone: 717-426-1131 Fax: 717-426-2068 |
Mr. Stephen K Rittenhouse, D.O. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1159 River Road, Marietta, PA 17547 Phone: 717-426-1131 Fax: 717-426-2068 |
Nelson R Lehman, M.D. Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 1159 River Rd, Marietta, PA 17547 Phone: 717-426-1131 Fax: 717-426-2068 |
Gerald E Miller, M.D. Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 1159 River Rd, Marietta, PA 17547 Phone: 717-426-1131 Fax: 717-426-2068 |
News Archive
Alzheimer's could be detected early using a blood test
Researchers from the ARTFL-LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD) research consortium, have reported that a blood test could soon be an important diagnostic tool in detecting the abnormal proteins deposits in the brain that lead to the progressive and debilitating condition of Alzheimer's disease. The study titled, "Diagnostic value of plasma phosphorylated tau181 in Alzheimer's disease and frontotemporal lobar degeneration," was published in today's issue of the journal Nature Medicine.
Researchers uncover new disease mechanism in patients with CGD
Infection researchers at Umeå University have uncovered a new disease mechanism in patients with Chronic Granulomatous Disease in an international clinical collaboration with the Children's Hospital in Zurich.
Link between HPV and cervical cancer
Scientists in the United States have carried out a review of research to determine the link between persistent HPV (human papillomavirus) infection and cervical cancer.
Ceragenix awarded $2.87M NIH grant to develop a drug for treating Clostrdium difficile and Shigella
Ceragenix Pharmaceuticals, Inc. ("Ceragenix") (OTCBB:CGXP), a medical device company focused on infectious disease and dermatology, today announced that the National Institutes of Health ("NIH") has awarded a $2.87 million grant to fund the pre clinical development of a Ceragenin™based oral drug to treat two common and potentially deadly gastrointestinal infections: Clostrdium difficile and Shigella.
› Verified 6 days ago